NCT06811493

Brief Summary

comparison of the feasibility and efficacy of the one-level and two-level thoracic ESP block and their effect on intraoperative and postoperative analgesia in bariatric surgeries.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jun 2024

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2024

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

January 31, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

February 6, 2025

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 24, 2026

Completed
Last Updated

April 22, 2026

Status Verified

April 1, 2026

Enrollment Period

1.6 years

First QC Date

January 31, 2025

Last Update Submit

April 17, 2026

Conditions

Keywords

erector spinae plane block, bariatric surgery, obese patients

Outcome Measures

Primary Outcomes (1)

  • • visual analog scale (VAS) scores during first 24 hour postoperative

    Pain will be classified as mild (VAS 1-3), moderate (VAS 4-6), and severe (VAS 7-10) .

    post-operative period at 1 h (hour) , 2 h, 4 h, 8h, 12h,18h and 24 h (hours).

Study Arms (2)

two levels of bilateral thoracic erector spinae plane block

ACTIVE COMPARATOR

two level of bilateral thoracic erector spinae plane block combined with general anesthesia in laparoscopic bariatric Surgery for obese patients

Procedure: bilateral thoracic erector spinae plane block combined with general anesthesia in laparoscopic bariatric surgery in obese patients

one level of bilateral thoracic erector spinae plane block

ACTIVE COMPARATOR

one level of bilateral thoracic erector spinae plane block combined with general anesthesia in laparoscopic bariatric Surgery for obese patients

Procedure: bilateral thoracic erector spinae plane block combined with general anesthesia in laparoscopic bariatric surgery in obese patients

Interventions

using the in-plane approach, in caudal -to- cephalad direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle. the block will be performed bilaterally by injecting 60 mL of 0.25% bupivacaine (15 mL into each of four site) into the fascial plane between the deep surface of the Erector Spinae muscle and the bilateral transverse processes of the thoracic vertebrae 5 and 10 (at the most lateral part of the transverse process)

one level of bilateral thoracic erector spinae plane blocktwo levels of bilateral thoracic erector spinae plane block

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Patient age ranges 18 to 60 years old
  • Obese patients ; Body mass index(BMI) ≥ 35 - 50 kg/m2
  • American Society of Anesthesiologists (ASA) physical status classes II to III
  • Patients scheduled for laparoscopic bariatric surgery i.e. sleeve gastrectomy and/or Roux-en-Y gastric bypass (RYGB) surgeries

You may not qualify if:

  • Refusal of regional block
  • Patients with neurological, psychological disorders or those lacking cooperation
  • Patients scheduled for concomitant laparoscopic cholecystectomy or paraumbilical hernia repair or those with history of previous bariatric surgery or obstructive sleep apnea
  • Patients with anatomic abnormalities at site of injection, skin lesions or wounds at site of proposed needle insertion.
  • Patients with bleeding disorders defined as (INR \>1.4) and/ or (platelet count \<100,000/µL)
  • Patients with hepatic disease e.g. liver cell failure or hepatic malignancy or hepatic enlargement.
  • Patients who are allergic to amide local anesthetics.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cairo University

Cairo, Egypt

Location

MeSH Terms

Interventions

Anesthesia, General

Intervention Hierarchy (Ancestors)

AnesthesiaAnesthesia and Analgesia

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer

Study Record Dates

First Submitted

January 31, 2025

First Posted

February 6, 2025

Study Start

June 1, 2024

Primary Completion

December 31, 2025

Study Completion

February 24, 2026

Last Updated

April 22, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations